EP. 1: Patient Journey and Development of Metastatic Breast Cancer
Watch
EP. 2: Patient, Advocate, and Payer on Value-Based Care for mBC
EP. 3: Provider Perspective on Value-Based Care for mBC
EP. 4: Patient Cost Burden for Metastatic Breast Cancer Therapy
EP. 5: Provider Responsibility to Cost Burden for mBC Therapy
EP. 6: Value-Based Care vs Cost of Treatment for mBC
EP. 7: First-line Therapy for HR-Positive, HER2-Negative mBC
EP. 8: Pivotal Studies for CDK4/6 Inhibitors
EP. 9: Role of CDK4/6 Inhibitors and Patient Selection
EP. 10: Distinguishing Among the Available CDK4/6 Inhibitors
EP. 11: Formulary Consideration and Clinical Impact of Cost
EP. 12: Breast Cancer Management: Global Cost of Care
EP. 13: Defining Episode of Care in Metastatic Disease
EP. 14: Breast Cancer Pathway Guidelines for Practitioners
EP. 15: Payer Approval for Frontline Options: Restrictive or Broad?
EP. 16: The Impact of Patient Preference on Payer Compliance
EP. 17: Breast Cancer Treatment: How COVID-19 Has Altered Care
EP. 18: Adjuvant CDK4/6 Inhibition: When it Will Become Routine
EP. 19: Development of Clinical Pathways and Patient Characteristics
EP. 20: Adding Multiple in a Class and Measuring Success of Pathways
EP. 21: Outcomes and Future of Clinical Pathways
